Cyclin Dependent Kinase 4/6 Inhibitors in Early Breast Cancer

  • Cyclin-dependent kinase 4 / 6 (CDK4/6) inhibitors have become integral to the treatment of HR+ / HER2- breast cancer
  • Approved in 2015 for use in the metastatic setting and most recently in the adjuvant setting, CDK 4 / 6 inhibitors have revolutionized treatment in both endocrine-sensitive and endocrine-resistant settings and in premenopausal and postmenopausal women
  • Many questions remain regarding the optimal use of these medications in clinical practice.
  • The three main studies that looked at the role of adjuvant CDK 4 / 6 inhibitors, including the PALLAS and PENELOPE-B trials, in which palbociclib showed no benefit in invasive disease-free survival
  • In contrast, in the monarchE trial, abemaciclib showed a robust benefit in preventing recurrence, which was sustained after longer follow-up, as reported at the San Antonio Breast Cancer Symposium 2022
Breast Cancer Risk Assessment and Screening
Key Takeaways in Early Breast Cancer From AACR 2023
Metastatic Breast Cancer: A Review of 3 Cases and Palliative Care

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s